CEA-Leti joins antibiotic resistance project
CEA-Leti has joined 14 European research centres and private companies in a Horizon 2020 project to combat multidrug-resistant tuberculosis (MDR TB) and methicillin-resistant staphylococcus aureus (MRSA).
The Nanotherapeutics for Antibiotic Resistant Emerging Bacterial Pathogens (NAREB) project aims to focus on the design, preparation and optimisation of several nanoformulations of current antibiotics and novel antibacterial drugs to improve the treatment of both infections in European MDR TB patients.
The project’s goals include selecting antibacterial molecules and designing nanocarriers with strong antibacterial activity; in vitro and in vivo testing of the best therapeutic combinations, including innovative genomic and bioimaging approaches; assessing safety, regulatory, and production (GLP/GMP) aspects for the most promising nanoformulations; and establishing a clinical development plan for preparatory work for the subsequent clinical testing of the selected nanoformulations.
The World Health Organization has recognised antibiotic resistance as a major threat to global health and is predicting a forthcoming disaster due to the rapid and unchecked increase in antimicrobial resistance, largely as a consequence of the scarcity of new classes of antibacterials in development.
